To demonstrate pan-subtype efficacy, we assessed the ability of HIV SMRTcap to characterize integrated provirus from in vitro infections of SupT1/CCR5 or SupT1/CXCR4 cells across the four major global HIV-1 subtypes (A, B, C, and D) (Figure 3; (42–44)). This evidence concerns the gene CCR5 and infection.